Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

Abstract

Introduction: Fluvoxamine is one of the most widely prescribed antidepressants and presents data from 30 years of clinical experience.

Areas covered: The present review article describes the pharmacokinetic properties of fluvoxamine and their implications for the treatment of anxiety disorders (AD). A search in the main database sources (Medline, Isi Web of Knowledge and Medscape) has been performed in order to obtain a comprehensive and balanced evaluation of fluvoxamine about the implications of its pharmacokinetic properties for the treatment of AD. The word ‘fluvoxamine’ has been associated with ‘pharmacokinetics’, ‘interactions’, ‘generalized anxiety disorder’, ‘social anxiety disorder’, ‘social phobia’, ‘panic disorder’, ‘anxiety’ and ‘tolerability’. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles have been selected.

Expert opinion: Fluvoxamine presents high tolerability and safety so that it can be considered as a therapeutic option in case of panic disorder and social anxiety disorder. In contrast, its weakness is in extended interaction with CYP450 enzymatic system that may limit its use in elderly or patients with medical comorbidities. Finally, data of efficacy about generalized anxiety disorder are very limited and preliminary so that it is not possible to draw any sound conclusions.

Keywords:

• anxiety disorder
• fluvoxamine
• pharmacokinetics

Declaration of interest

AC Altamura has served as a consultant and/or on the advisory board for Roche, Merck, AstraZeneca, Bristol-Myers Squibb, Janssen and Lundbeck. M Buoli has served as a consultant for Roche. A Caldiroli declares no conflicts of interest.